B-intervention	0	10	Menopausal
I-intervention	11	18	hormone
I-intervention	19	26	therapy
I-intervention	27	28	(
I-intervention	28	30	HT
I-intervention	30	31	)
O	32	34	in
O	35	43	patients
O	44	48	with
O	49	55	breast
O	56	62	cancer
O	62	63	.

O	64	66	To
O	67	73	assess
O	74	77	the
O	78	84	effect
O	85	87	of
O	88	98	menopausal
O	99	106	hormone
O	107	114	therapy
O	115	116	(
O	116	118	HT
O	118	119	)
O	120	122	on
O	123	135	reoccurrence
O	135	136	,
O	137	143	cancer
O	143	144	-
O	144	151	related
O	152	161	mortality
O	161	162	,
O	163	166	and
O	167	174	overall
O	175	184	mortality
O	185	190	after
O	191	192	a
O	193	202	diagnosis
O	203	205	of
O	206	212	breast
O	213	219	cancer
O	219	220	.

O	221	223	We
O	224	233	performed
O	234	235	a
O	236	248	quantitative
O	249	255	review
O	256	258	of
O	259	262	all
O	263	270	studies
O	271	280	reporting
O	281	291	experience
O	292	296	with
O	297	307	menopausal
O	308	310	HT
O	311	314	for
O	315	326	symptomatic
O	327	330	use
O	331	336	after
O	337	338	a
O	339	348	diagnosis
O	349	351	of
O	352	358	breast
O	359	365	cancer
O	365	366	.

O	367	372	Rates
O	373	375	of
O	376	388	reoccurrence
O	388	389	,
O	390	396	cancer
O	396	397	-
O	397	404	related
O	405	414	mortality
O	414	415	,
O	416	419	and
O	420	427	overall
O	428	437	mortality
O	438	442	were
O	443	453	calculated
O	454	456	in
O	457	461	this
O	462	468	entire
O	469	474	group
O	474	475	.

O	476	477	A
O	478	486	subgroup
O	487	495	analysis
O	496	499	was
O	500	509	performed
O	510	512	in
O	513	520	studies
O	521	526	using
O	527	528	a
O	529	536	control
O	537	547	population
O	548	550	to
O	551	557	assess
O	558	561	the
O	562	566	odds
O	567	572	ratio
O	573	575	of
O	576	582	cancer
O	583	595	reoccurrence
O	596	599	and
O	600	609	mortality
O	610	612	in
O	613	620	hormone
O	621	626	users
O	627	633	versus
O	634	637	non
O	637	638	-
O	638	643	users
O	643	644	.

O	645	652	Fifteen
O	653	660	studies
O	661	673	encompassing
B-intervention-participants	674	678	1416
O	679	685	breast
O	686	692	cancer
O	693	702	survivors
O	703	708	using
O	709	711	HT
O	712	716	were
O	717	727	identified
O	727	728	.

O	729	734	Seven
O	735	742	studies
O	743	751	included
O	752	753	a
B-control	754	761	control
I-control	762	767	group
O	768	777	comprised
O	778	780	of
B-control-participants	781	785	1998
O	786	794	patients
O	794	795	.

O	796	801	Among
O	802	805	the
O	806	810	1416
O	811	813	HT
O	814	819	users
O	819	820	,
B-outcome	821	833	reoccurrence
O	834	837	was
O	838	843	noted
O	844	846	in
B-iv-bin-percent	847	849	10
I-iv-bin-percent	849	850	.
I-iv-bin-percent	850	851	0
I-iv-bin-percent	851	852	%
O	853	854	(
O	854	856	95
O	856	857	%
O	858	860	CI
O	860	861	:
O	862	863	8
O	863	864	.
O	864	865	4
O	865	866	-
O	866	868	11
O	868	869	.
O	869	870	6
O	870	871	%
O	871	872	)
O	872	873	.

B-outcome	874	880	Cancer
I-outcome	880	881	-
I-outcome	881	888	related
I-outcome	889	898	mortality
O	899	907	occurred
O	908	910	at
O	911	912	a
O	913	917	rate
O	918	920	of
B-iv-bin-percent	921	922	2
I-iv-bin-percent	922	923	.
I-iv-bin-percent	923	924	6
I-iv-bin-percent	924	925	%
O	926	927	(
O	927	929	95
O	929	930	%
O	931	933	CI
O	933	934	:
O	935	936	1
O	936	937	.
O	937	938	8
O	938	939	-
O	939	940	3
O	940	941	.
O	941	942	7
O	942	943	%
O	943	944	)
O	944	945	,
O	946	951	while
B-outcome	952	959	overall
I-outcome	960	969	mortality
O	970	973	was
B-iv-bin-percent	974	975	4
I-iv-bin-percent	975	976	.
I-iv-bin-percent	976	977	5
I-iv-bin-percent	977	978	%
O	979	980	(
O	980	982	95
O	982	983	%
O	984	986	CI
O	986	987	:
O	988	989	3
O	989	990	.
O	990	991	4
O	991	992	-
O	992	993	5
O	993	994	.
O	994	995	8
O	995	996	%
O	996	997	)
O	997	998	.

O	999	1007	Compared
O	1008	1010	to
O	1011	1014	non
O	1014	1015	-
O	1015	1020	users
O	1020	1021	,
O	1022	1030	patients
O	1031	1036	using
O	1037	1039	HT
O	1040	1043	had
O	1044	1045	a
O	1046	1055	decreased
B-outcome	1056	1062	chance
I-outcome	1063	1065	of
I-outcome	1066	1078	reoccurrence
I-outcome	1079	1082	and
I-outcome	1083	1089	cancer
I-outcome	1089	1090	-
I-outcome	1090	1097	related
I-outcome	1098	1107	mortality
O	1108	1112	with
O	1113	1121	combined
O	1122	1126	odds
O	1127	1132	ratio
O	1133	1135	of
O	1136	1137	0
O	1137	1138	.
O	1138	1139	5
O	1140	1141	(
O	1141	1143	95
O	1143	1144	%
O	1145	1147	CI
O	1147	1148	:
O	1149	1150	0
O	1150	1151	.
O	1151	1152	2
O	1152	1153	-
O	1153	1154	0
O	1154	1155	.
O	1155	1156	7
O	1156	1157	)
O	1158	1161	and
O	1162	1163	0
O	1163	1164	.
O	1164	1165	3
O	1166	1167	(
O	1167	1169	95
O	1169	1170	%
O	1171	1173	CI
O	1173	1174	:
O	1175	1176	0
O	1176	1177	.
O	1177	1178	0
O	1178	1179	-
O	1179	1180	0
O	1180	1181	.
O	1181	1182	6
O	1182	1183	)
O	1183	1184	,
O	1185	1197	respectively
O	1197	1198	.

O	1199	1201	In
O	1202	1205	our
O	1206	1212	review
O	1212	1213	,
O	1214	1224	menopausal
O	1225	1227	HT
O	1228	1231	use
O	1232	1234	in
O	1235	1241	breast
O	1242	1248	cancer
O	1249	1258	survivors
O	1259	1262	was
O	1263	1266	not
O	1267	1277	associated
O	1278	1282	with
O	1283	1292	increased
B-outcome	1293	1299	cancer
I-outcome	1300	1312	reoccurrence
O	1312	1313	,
B-outcome	1314	1320	cancer
I-outcome	1320	1321	-
I-outcome	1321	1328	related
I-outcome	1329	1338	mortality
I-outcome	1339	1341	or
I-outcome	1342	1347	total
I-outcome	1348	1357	mortality
O	1357	1358	.

O	1359	1366	Despite
O	1367	1378	conflicting
O	1379	1387	opinions
O	1388	1390	on
O	1391	1395	this
O	1396	1401	issue
O	1401	1402	,
O	1403	1405	it
O	1406	1408	is
O	1409	1418	important
O	1419	1422	for
O	1423	1430	primary
O	1431	1435	care
O	1436	1446	physicians
O	1447	1449	to
O	1450	1454	feel
O	1455	1466	comfortable
O	1467	1476	medically
O	1477	1485	managing
O	1486	1489	the
O	1490	1500	increasing
O	1501	1507	number
O	1508	1510	of
O	1511	1517	breast
O	1518	1524	cancer
O	1525	1534	survivors
O	1534	1535	.

O	1536	1538	In
O	1539	1542	the
O	1543	1549	subset
O	1550	1552	of
O	1553	1558	women
O	1559	1563	with
O	1564	1570	severe
O	1571	1581	menopausal
O	1582	1590	symptoms
O	1590	1591	,
O	1592	1594	HT
O	1595	1602	options
O	1603	1609	should
O	1610	1612	be
O	1613	1621	reviewed
O	1622	1624	if
O	1625	1628	non
O	1628	1629	-
O	1629	1637	hormonal
O	1638	1645	methods
O	1646	1649	are
O	1650	1661	ineffective
O	1661	1662	.

O	1663	1669	Future
O	1670	1676	trials
O	1677	1683	should
O	1684	1689	focus
O	1690	1692	on
O	1693	1699	better
O	1700	1704	ways
O	1705	1707	to
O	1708	1716	identify
O	1717	1723	breast
O	1724	1730	cancer
O	1731	1740	survivors
O	1741	1744	who
O	1745	1748	may
O	1749	1755	safely
O	1756	1763	benefit
O	1764	1768	from
O	1769	1771	HT
O	1772	1778	versus
O	1779	1784	those
O	1785	1788	who
O	1789	1793	have
O	1794	1795	a
O	1796	1807	substantial
O	1808	1812	risk
O	1813	1815	of
O	1816	1828	reoccurrence
O	1829	1833	with
O	1834	1836	HT
O	1837	1840	use
O	1840	1841	.
